Pfizer and its partner BioNTech said their COVID-19 vaccine is safe and 90.7 percent effective against symptomatic COVID-19 in children ages 5 to 11.
The companies revealed the data in a document posted Friday ahead of a meeting of advisers to the U.S. Food and Drug Administration (FDA) scheduled for next Tuesday.
Pfizer and BioNTech are applying FDA emergency use authorization (EUA) of a two-dose regimen of their 10-microgram dose for children ages 5 to 11. The two doses would be administered three weeks apart.
The data show that the two-dose primary series of the vaccine given to children from 5 to less than 12 years of age confers a high degree of protective efficacy against COVID-19 during a period when the Delta variant of concern predominates in the United States.
The FDA’s Vaccines and Related Biological Products Advisory Committee is scheduled to meet on Oct. 26 to discuss whether to authorize the vaccine for children ages 5 to 11.
If authorized, it would be the first COVID-19 vaccine for younger children.
Fahad is an entrepreneur and a marketing enthusiast who loves to write on trending topics. He loves travelling & playing tennis is what he does in his leisure time. He tweets @fahad164.
Email:- fahad164@gmail.com , fahad@themediaparadigm.com
